Overview
Paradox Biosciences develops next-generation small-molecule therapeutics targeting synaptic plasticity pathways for the treatment of treatment-resistant depression and PTSD.
More in Neuropharmaceuticals
Latest industry news
A New Neurotech Startup Launches to Challenge Sam Altman's Merge Labs in the BCI Race
2026-10-10 · Industry
Butterfly Network Teams Up With Bridge Neurotech to Chase Ultrasound-Based Brain-Computer Interfaces
2026-10-09 · Industry
Paradromics Hits Four-Year Mark for Stable Neural Recording in Landmark BCI Durability Milestone
2026-10-08 · Research
INBRAIN and MINIGRAPH Consortium Bring Robotic Precision to Graphene BCI Implantation
2026-10-07 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, CA
Funding
Series A — $42M
Website
paradoxbiosciences.comListed
2026-08-31
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →